Background: MDMA-assisted therapy (MDMA-AT) is an emerging treatment modality, with recent phase 3 trials indicating its potential for regulatory approval. Central to this therapy is the role of touch, yet its empirical evaluation in MDMA-AT, and psychotherapy in general, remains limited. The use of touch in combination with MDMA raises concerns about power imbalances and ethical boundaries.
Methods: This article reviews existing literature on therapeutic touch and introduces the Touch Outcomes Measurement Inventory (TOMI). The TOMI is developed to assess client perceptions of touch in MDMA-AT, addressing a critical gap in the current research landscape.
Results: The main outcome of this research is the creation of TOMI, a tool aimed at evaluating the impact of touch on clients in MDMA-AT. The review highlights the lack of empirical evidence in this area and the necessity for such a measure.
Discussion: With the increasing likelihood of MDMA-AT becoming a widely used therapy, understanding how therapeutic touch affects clients is imperative. This article emphasizes the need for evidence-based and ethical guidelines for the use of touch in MDMA-AT. The development of TOMI is a step towards achieving this, providing a means for researchers and program evaluators to assess the implications of touch in MDMA-AT and psychedelic-assisted therapy more generally.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658647 | PMC |
http://dx.doi.org/10.1089/psymed.2023.0033 | DOI Listing |
Psychedelic Med (New Rochelle)
March 2024
Department of Mental Health, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
Background: MDMA-assisted therapy (MDMA-AT) is an emerging treatment modality, with recent phase 3 trials indicating its potential for regulatory approval. Central to this therapy is the role of touch, yet its empirical evaluation in MDMA-AT, and psychotherapy in general, remains limited. The use of touch in combination with MDMA raises concerns about power imbalances and ethical boundaries.
View Article and Find Full Text PDFIn August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!